Liz Higgins - Haematology Association of Ireland

More documents

Recommendations

Info

Plerixafor: a first in class stem cell mobilising agent Structural formula of plerixafor 16 Plerixafor is a first in class CXCR4 antagonist that mobilises stem cells from the bone marrow, increasing their number in peripheral blood Its mode of action is to block the chemokine receptor 4 (CXCR4, found on stems cells), preventing binding. Menu
Mechanism of action of Plerixafor Plerixafor blocks the CXCR4–SDF-1α interaction, releasing stem cells from the bone marrow into the circulating blood. Menu
Page 1 and 2: AutologousPeripheral Blood Stem Cel
Page 3 and 4: PBSCH 2008 71 2009 75 2010 54 to da
Page 5 and 6: PBSCT PBSCT involves eliminating an
Page 7 and 8: Cancers treated by Autologous PBSCT
Page 9 and 10: Sources of Bone Marrow Stem Cells B
Page 11 and 12: PBSCH COMMISSION DIRECTIVE 2006/17/
Page 13 and 14: PBSC Mobilisation Initial Review FB
Page 15 and 16: Cyclophosphamide 2g/m 2 Chemo on Mo
Page 17 and 18: ICE Etoposide 10mg/m 2 Day 1,2,3.,
Page 19 and 20: Eshap Commence Tuesday Day 12-14
Page 22 and 23: Apheresis guidelines
Page 24: COBE
Page 27 and 28: Autologous HSCT in multiple myeloma
Page 29: Indication Plerixafor is indicated
Page 33 and 34: Plerixafor increases predictability

Liz Higgins - Haematology Association of Ireland

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?